lupus anticoagulant , LAC (Abkürzung)

Patients with no history of thrombosis and a lupus anticoagulant should probably be observed.

Miscarriages may be more prevalent in patients with a lupus anticoagulant.

Both words in the term "lupus anticoagulant" can be misleading:

Increased levels of other substances (antiphospholipid or lupus anticoagulant).

The two antibodies implicated are anticardiolipin and lupus anticoagulant.

The disease name is a misnomer: Lupus anticoagulant is actually a prothrombotic agent.

The most common inhibitor is a nonspecific inhibitor such as a lupus anticoagulant.

This can be contrasted with lupus anticoagulant which inhibits agglutination in the presence of thrombin.

A prolonged clotting time of 30 seconds or greater that does not correct despite the mixing study suggests the presence of a lupus anticoagulant.

Also, it was proposed that AAHA is responsible for lupus anticoagulant.

Nonspecific inhibitors like the lupus anticoagulant usually are not time dependent; the immediate mixture will show prolongation.

Antiphospholipid syndrome (such as lupus anticoagulant)

There is some evidence to suggest that NPT may be less accurate for certain patients, for example those who have the lupus anticoagulant.

However, like Apo-H the Lupus anticoagulant inhibits factor Xa generation.

Anti-prothrombin antibodies in autoimmune disease may be a factor in the formation of the lupus anticoagulant also known as (antiphospholipid syndrome).

Patients with a well-documented (i.e., present at least twice) lupus anticoagulant and a history of thrombosis should be considered candidates for indefinite treatment with anticoagulants.

Lupus anticoagulant, a circulating inhibitor predisposing for thrombosis, may skew PT results, depending on the assay used.

The ECT is also unaffected by prior treatment with coumadin or the presence of phospholipid-dependent anticoagulants, such as lupus anticoagulant.

Lupus anticoagulant detected on 2 occasions not less than 12 weeks apart according to the guidelines of the International Society of Thrombosis and Hemostasis.

Treatment for a lupus anticoagulant is usually undertaken in the context of documented thrombosis, such as extremity phlebitis or dural sinus vein thrombosis.

This is normally achieved by differentiating the effects of a lupus anticoagulant on factor assays from the effects of a specific coagulation factor antibody.

Anti-thrombin antibodies are autoantibodies directed against thrombin that may constitute a fraction of lupus anticoagulant and are seen an increased levels in systemic lupus erythematosus.

A subset of AHAA appear to mimic the activity of lupus anticoagulant and increase Apo-H binding to phospholipids.

Lupus anticoagulant (also known as lupus antibody, LA, or lupus inhibitors) is an immunoglobulin that binds to phospholipids and proteins associated with the cell membrane.

In this test, the inhibitory effect of lupus anticoagulants on phospholipids in the dRVVT can be overcome by adding an excess of phospholipid to the assay.